

Appendix VI – Univariable (T-test for comparisons) and multivariable results by liposomal bupivacaine use in patients receiving a peripheral nerve block and neuraxial anesthesia.

	Univariable results			Multivariable results	
	Use of liposomal bupivacaine			Use of liposomal bupivacaine	
	Yes (n=538)	No (n=8,232)	P-value	Yes (Reference=No)	P-value
	Median (IQR)	Median (IQR)		Percent change (95% CI)	
<i>INPATIENT OPIOID PRESCRIPTION</i>					
Total Opioids (mg OME)	153 (90-243)	248 (163-360)	<0.0001	-6.1% (-14.6%; 3.2%)	>0.999
Day 0 Opioids (mg OME)	70 (38-105)	110 (60-160)	<0.0001	-5.0% (-14.3%; 5.2%)	>0.999
Day 1 Opioids (mg OME)	45 (23-70)	64 (30-107)	<0.0001	-14.2% (-24.8%; -2.1%)	0.0090
Day 1+ Opioids (mg OME)	30 (0-60)	50 (23-95)	<0.0001	-2.2% (-16.2%; 14.0%)	>0.999
<i>RESOURCE UTILIZATION</i>					
Cost of Hospitalization (US dollars)	16,833 (13,808-19,195)	15,222 (12,880-18,632)	<0.0001	5.0% (1.0%; 9.2%)	<0.0001
Length of Stay (days)	2 (2-3)	3 (2-3)	<0.0001	0.6% (-5.3%; 6.8%)	>0.999

Multivariable models adjusted for: age, volume of annual total knee arthroplasties per hospital, hospital size, Charlson-Deyo Index, sex, race, year, insurance, teaching status, hospital area, general anesthesia use, neuraxial anesthesia use, liposomal bupivacaine, NSAIDs, Cox-2 inhibitors, ketamine, gabapentinoids, patient-controlled analgesia, IV acetaminophen, and the comorbidities for substance use/abuse, pain conditions, and psychiatric conditions.

OME: Oral morphine equivalents

IQR: Interquartile range

CI: Confidence interval

NSAIDs: Nonsteroidal antiinflammatory drugs

Cox-2: Cyclooxygenase-2